Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca, Eli Lilly and Cancer Dominate 2016 EU New Drug Approvals

Jan 12 2017

• By Ian Schofield

Biopharma In Perspective 2016-2017

Related Content

No Dominant Sponsors In US FDA's 2016 Novel Approvals Class

Jan 06 2017

Oncology Captures One In Three New EU Drug Approvals In 2016

Dec 23 2016

It’s Started: EMA Proactively Publishes Clinical Data On New Drugs

Oct 21 2016

Amgen's Parsabiv's EU Approval Contrasts With US FDA Rejection

Nov 17 2016

Related Companies

Merck & Co., Inc.

Eli Lilly and Company

AstraZeneca PLC

Intercept Pharmaceuticals, Inc.

AGC Biologics SPA

Amryt Pharma plc

Amicus Therapeutics, Inc.

Pfizer Inc.

AbbVie Inc.

Roche Holding AG

Takeda Pharmaceutical Co. Ltd.

Johnson & Johnson

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Les Laboratoires Servier

Amgen, Inc.

BioProjet SCR

UCB S.A.

Gilead Sciences, Inc.

MedImmune LLC

CSL Limited

Swedish Orphan Biovitrum AB

Biogen, Inc.

GSK plc

Actelion Pharmaceuticals Ltd.

Teva Pharmaceutical Industries Ltd.

Allergan plc

Additional Topics

Europe Approvals Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window